Open AccessExposure–Efficacy Analyses Support Optimal Dosing Regimens of Ceftolozane/Tazobactam in Participants with Hospital-Acquired/Ventilator-Associated Bacterial Pneumonia in ASPECT-NP
Author(s) -
Wei Gao,
Julie Passarell,
Yogesh T. Patel,
Zufei Zhang,
Gina Lin,
Jill FiedlerKelly,
Christopher Bruno,
Elizabeth G. Rhee,
Carisa S De Anda,
HwaPing Feng
Publication year - 2022
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.01399-21
Subject(s) - tazobactam , medicine , hospital acquired pneumonia , pharmacodynamics , pneumonia , population , dosing , bacterial pneumonia , ventilator associated pneumonia , pharmacokinetics , piperacillin/tazobactam , clinical endpoint , antibiotics , clinical trial , microbiology and biotechnology , biology , pseudomonas aeruginosa , piperacillin , antibiotic resistance , bacteria , genetics , environmental health , imipenem
An exposure–efficacy analysis of the phase 3 ASPECT-NP trial was performed to evaluate the relationship between plasma exposure of ceftolozane and tazobactam and efficacy endpoints (primary: 28-day all-cause mortality; key secondary: clinical cure at test-of-cure visit) in adult participants with hospital-acquired or ventilator-associated bacterial pneumonia (HABP/VABP). Participants (N = 231) from the ceftolozane/tazobactam treatment group in the intention-to-treat population who had pharmacokinetic data available and relevant baseline lower respiratory tract (LRT) pathogen(s) susceptibility data were included.